X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (430) 430
Publication (128) 128
Paper (110) 110
Book / eBook (20) 20
Report (14) 14
Book Chapter (8) 8
Newspaper Article (7) 7
Book Review (5) 5
Newsletter (4) 4
Patent (3) 3
Dissertation (2) 2
Magazine Article (1) 1
Reference (1) 1
Streaming Audio (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
physics (121) 121
experiment (114) 114
particle physics (109) 109
high energy physics - experiment (108) 108
index medicus (90) 90
physics - high energy physics - experiment (87) 87
humans (82) 82
high energy physics (68) 68
particle physics - experiment (67) 67
physics of elementary particles and fields (63) 63
hematology (39) 39
male (39) 39
female (38) 38
nuclear experiment (36) 36
elementary particles, quantum field theory (35) 35
quantum field theories, string theory (35) 35
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (34) 34
hadron-hadron scattering (34) 34
oncology (34) 34
quantum physics (33) 33
classical and quantum gravitation, relativity theory (32) 32
cms (30) 30
phenomenology (29) 29
aged (27) 27
adult (26) 26
middle aged (25) 25
física (24) 24
article (22) 22
astrophysics (22) 22
cern lhc coll (22) 22
experimental results (22) 22
genetics & heredity (21) 21
high energy astrophysical phenomena (21) 21
7000 gev-cms (19) 19
abridged index medicus (18) 18
leukemia, lymphocytic, chronic, b-cell - drug therapy (18) 18
chronic lymphocytic-leukemia (17) 17
research (17) 17
animals (16) 16
physics, particles & fields (16) 16
care and treatment (15) 15
chronic lymphocytic leukemia (15) 15
ibrutinib (15) 15
aged, 80 and over (14) 14
cll (14) 14
hemic and lymphatic diseases (14) 14
instrumentation and detectors (14) 14
p p: interaction (14) 14
proto-oncogene proteins c-bcl-2 - antagonists & inhibitors (14) 14
risk factors (14) 14
treatment outcome (14) 14
genetic aspects (12) 12
open-label (12) 12
analysis (11) 11
antineoplastic agents - therapeutic use (11) 11
inhibitor (11) 11
rituximab (11) 11
survival (11) 11
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (10) 10
apoptosis (10) 10
astronomy & astrophysics (10) 10
diagnosis (10) 10
expression (10) 10
immune system diseases (10) 10
leukemia (10) 10
leukemia, lymphocytic, chronic, b-cell - pathology (10) 10
mutation (10) 10
mutations (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
cancer (9) 9
medical research (9) 9
nuclear physics (9) 9
surgery (9) 9
usage (9) 9
venetoclax (9) 9
bcl2 (8) 8
bridged bicyclo compounds, heterocyclic - administration & dosage (8) 8
collisions (8) 8
fludarabine (8) 8
genetics (8) 8
health aspects (8) 8
lymphomas (8) 8
sulfonamides - administration & dosage (8) 8
acute myeloid-leukemia (7) 7
cell biology (7) 7
child (7) 7
chronic lymphatic leukemia (7) 7
clinical trials (7) 7
cyclophosphamide (7) 7
disease (7) 7
disease-free survival (7) 7
fizikai tudományok (7) 7
genomics (7) 7
hematology, oncology and palliative medicine (7) 7
large hadron collider (7) 7
leukemia, lymphocytic, chronic, b-cell - genetics (7) 7
management (7) 7
medicine, general & internal (7) 7
patients (7) 7
physics and astronomy (7) 7
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (5) 5
Robarts - Stacks (5) 5
Trinity College (John W Graham) - Stacks (3) 3
UTL at Downsview - May be requested (3) 3
Victoria University Emmanuel College - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Knox College (Caven) - Stacks (2) 2
Regis College - Stacks (2) 2
St. Michael's College (John M. Kelly) - 3rd Floor (2) 2
Business (Joseph L Rotman) - Stacks (1) 1
Criminology - Stacks (1) 1
Gerstein Science - Stacks (1) 1
Knox College (Caven) - Reference (1) 1
Knox College (Caven) - Storage (1) 1
Law (Bora Laskin) - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
Regis College - Reference (1) 1
Robarts - Reference (1) 1
Royal Ontario Museum - Rare Book (1) 1
St. Augustine's Seminary - Reference (1) 1
St. Augustine's Seminary - Stacks (1) 1
St. Michael's College (John M. Kelly) - Reference (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
Trinity College (John W Graham) - Reference (1) 1
Trinity College (John W Graham) - Storage (1) 1
Trinity College (John W Graham) - Wycliffe Storage (1) 1
UofT at Mississauga - Stacks (1) 1
Victoria University Emmanuel College - Birge Storage (1) 1
Victoria University Emmanuel College - Storage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. SY16-03 - SY16-03
Journal Article
Journal Article
Hematology, ISSN 1520-4391, 12/2017, Volume 2017, Issue 1, pp. 346 - 353
With the recent approval of several effective and well-tolerated novel agents (NAs), including ibrutinib, idelalisib, venetoclax, and obinutuzumab, patients... 
17P DELETION | IDELALISIB | RITUXIMAB | VENETOCLAX | IBRUTINIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | OPEN-LABEL | CLONAL EVOLUTION | HEMATOLOGY | FLUDARABINE | EDUCATION, SCIENTIFIC DISCIPLINES | PREVIOUSLY UNTREATED PATIENTS | Individualizing Therapy in Chronic Lymphocytic Leukemia
Journal Article
Hematology, ISSN 1520-4391, 12/2017, Volume 2017, Issue 1, pp. 354 - 357
Abstract A 70-year-old man with relapsed/refractory chronic lymphocytic leukemia has multiple comorbidities including atrial fibrillation (on warfarin for... 
Journal Article
Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 12/2017, Volume 2017, Issue 1, pp. 354 - 357
A 70-year-old man with relapsed/refractory chronic lymphocytic leukemia has multiple comorbidities including atrial fibrillation (on warfarin for... 
Individualizing Therapy in Chronic Lymphocytic Leukemia
Journal Article
Cancer Cell, ISSN 1535-6108, 02/2013, Volume 23, Issue 2, pp. 139 - 141
ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict... 
ABT-737 | CHRONIC LYMPHOCYTIC-LEUKEMIA | ONCOLOGY | FAMILY | CELL BIOLOGY
Journal Article
Blood, ISSN 0006-4971, 09/2018, Volume 132, Issue 12, pp. 1248 - 1264
Dysregulation of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins of the intrinsic apoptotic pathway is fundamental to the pathophysiology of many... 
IBRUTINIB PLUS VENETOCLAX | EFFICIENTLY INDUCES APOPTOSIS | BCL-2 FAMILY PROTEINS | CHRONIC LYMPHOCYTIC-LEUKEMIA | OBATOCLAX MESYLATE GX15-070 | OPEN-LABEL | ACUTE MYELOID-LEUKEMIA | BH3 MIMETIC ABT-737 | HEMATOLOGY | PHASE-I | CELL-DEATH
Journal Article
Cancer cell, ISSN 1535-6108, 2/2013, Volume 23, Issue 2, pp. 139 - 141
ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2010, Volume 28, Issue 18, p. 3098
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 22, pp. 2186 - 2187
Journal Article
Blood, ISSN 0006-4971, 05/2019, Volume 133, Issue 18, pp. 1922 - 1924
In this issue of Blood, Zelenetz et al(1) report the results of the phase 1b portion of the CAVALLI study, one of the first trials to explore a novel strategy... 
HEMATOLOGY
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
DOSE-ESCALATION | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | CLL | INTERNATIONAL WORKSHOP | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | INHIBITOR | PHASE-I | FLUDARABINE | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4395 - 4395
Abstract Background We previously found that the combination of ibrutinib (IBR) or duvelisib (DUV) with FCR leads to a high rate of MRD undetectability when... 
Journal Article
Blood, ISSN 0006-4971, 10/2018, Volume 132, Issue 15, pp. 1547 - 1548
In this issue of Blood, Rogers et al demonstrate that 3 novel agents approved for chronic lymphocytic leukemia (CLL), ibrutinib, venetoclax, and obinutuzumab,... 
HEMATOLOGY | CYCLOPHOSPHAMIDE | FLUDARABINE | VENETOCLAX | RITUXIMAB
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 2014, Volume 12, Issue 4, pp. 224 - 229
Journal Article
Future Oncology, ISSN 1479-6694, 2014, Volume 10, Issue 6, pp. 957 - 967
Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is critical for... 
ibrutinib | CLL | kinase | NHL | MCL | BTK | B-cell receptor | lymphocytosis | BENDAMUSTINE | SURVIVAL | MULTICENTER | PCI-32765 | OPEN-LABEL | TARGETING BTK | TRIAL | ONCOLOGY | RITUXIMAB | IN-VIVO | CHRONIC LYMPHOCYTIC-LEUKEMIA
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.